Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.
2.

Implications of prioritizing HIV cure: new momentum to overcome old challenges in HIV.

Tucker JD, Gilbertson A, Lo YR, Vitória M.

BMC Infect Dis. 2016 Mar 3;16:109. doi: 10.1186/s12879-016-1445-y.

3.

A novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression.

Braun DL, Kouyos R, Oberle C, Grube C, Joos B, Fellay J, McLaren PJ, Kuster H, Günthard HF.

PLoS One. 2014 Dec 9;9(12):e114111. doi: 10.1371/journal.pone.0114111. eCollection 2014.

4.

Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.

Brandenberg OF, Rusert P, Magnus C, Weber J, Böni J, Günthard HF, Regoes RR, Trkola A.

Retrovirology. 2014 Sep 25;11:75. doi: 10.1186/s12977-014-0075-y.

5.

How effectively can HIV phylogenies be used to measure heritability?

Shirreff G, Alizon S, Cori A, Günthard HF, Laeyendecker O, van Sighem A, Bezemer D, Fraser C.

Evol Med Public Health. 2013 Jan;2013(1):209-24. doi: 10.1093/emph/eot019. Epub 2013 Sep 13.

6.

Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns.

Schüpbach J, Gebhardt MD, Scherrer AU, Bisset LR, Niederhauser C, Regenass S, Yerly S, Aubert V, Suter F, Pfister S, Martinetti G, Andreutti C, Klimkait T, Brandenberger M, Günthard HF; Swiss HIV Cohort Study.

PLoS One. 2013 Aug 26;8(8):e71662. doi: 10.1371/journal.pone.0071662. eCollection 2013.

7.

Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions.

Brenner B, Wainberg MA, Roger M.

AIDS. 2013 Apr 24;27(7):1045-57. doi: 10.1097/QAD.0b013e32835cffd9. Review. No abstract available.

8.

The detection and management of early HIV infection: a clinical and public health emergency.

Smith MK, Rutstein SE, Powers KA, Fidler S, Miller WC, Eron JJ Jr, Cohen MS.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S187-99. doi: 10.1097/QAI.0b013e31829871e0. Review.

9.

Clinician practices and attitudes regarding early antiretroviral therapy in the United States.

Kurth AE, Mayer K, Beauchamp G, McKinstry L, Farrior J, Buchacz K, Donnell D, Branson B, El-Sadr W; HPTN (065) TLC-Plus Study Team.

J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):e65-9. doi: 10.1097/QAI.0b013e31826a184c.. Erratum in: J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):e68.

10.

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.

Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, Pedersen C, Okulicz JF, McClure M, Babiker A, Weber J, Fidler S; INSIGHT SMART and SPARTAC Investigators.

PLoS One. 2012;7(8):e43754. Epub 2012 Aug 31.

11.

Phylogenetic insights into regional HIV transmission.

Dennis AM, Hué S, Hurt CB, Napravnik S, Sebastian J, Pillay D, Eron JJ.

AIDS. 2012 Sep 10;26(14):1813-22. doi: 10.1097/QAD.0b013e3283573244.

12.

Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection.

Schüpbach J, Bisset LR, Gebhardt MD, Regenass S, Bürgisser P, Gorgievski M, Klimkait T, Andreutti C, Martinetti G, Niederhauser C, Yerly S, Pfister S, Schultze D, Brandenberger M, Schöni-Affolter F, Scherrer AU, Günthard HF; Swiss HIV Cohort Study.

BMC Infect Dis. 2012 Apr 12;12:88. doi: 10.1186/1471-2334-12-88.

13.

Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells.

Althaus CF, Vongrad V, Niederöst B, Joos B, Di Giallonardo F, Rieder P, Pavlovic J, Trkola A, Günthard HF, Metzner KJ, Fischer M.

Retrovirology. 2012 Mar 29;9:27. doi: 10.1186/1742-4690-9-27.

14.

Should we treat acute HIV infection?

O'Brien M, Markowitz M.

Curr HIV/AIDS Rep. 2012 Jun;9(2):101-10. doi: 10.1007/s11904-012-0113-0. Review.

15.

Recent HIV-1 infection contributes to the viral diffusion over the French territory with a recent increasing frequency.

Frange P, Meyer L, Deveau C, Tran L, Goujard C, Ghosn J, Girard PM, Morlat P, Rouzioux C, Chaix ML; French ANRS CO6 PRIMO Cohort Study Group.

PLoS One. 2012;7(2):e31695. doi: 10.1371/journal.pone.0031695. Epub 2012 Feb 14.

16.

Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050.

Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, Sabin ML, Makhlouf-Obermeyer C, De Filippo Mack C, Williams P, Jones L, Smyth C, Kutch KA, Ying-Ru L, Vitoria M, Souteyrand Y, Crowley S, Korenromp EL, Williams BG.

PLoS One. 2012;7(2):e30216. doi: 10.1371/journal.pone.0030216. Epub 2012 Feb 13.

17.

Screening acute HIV infections among Chinese men who have sex with men from voluntary counseling & testing centers.

Han X, Xu J, Chu Z, Dai D, Lu C, Wang X, Zhao L, Zhang C, Ji Y, Zhang H, Shang H.

PLoS One. 2011;6(12):e28792. doi: 10.1371/journal.pone.0028792. Epub 2011 Dec 14.

18.

Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.

Wyl Vv, Gianella S, Fischer M, Niederoest B, Kuster H, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Günthard HF; Swiss HIV Cohort Study-SHCS.

PLoS One. 2011;6(11):e27463. doi: 10.1371/journal.pone.0027463. Epub 2011 Nov 15.

19.

Universal testing and treatment as an HIV prevention strategy: research questions and methods.

Hayes R, Sabapathy K, Fidler S.

Curr HIV Res. 2011 Sep;9(6):429-45. Review.

20.

Cost-effectiveness of antiretroviral therapy for prevention.

Kahn JG, Marseille EA, Bennett R, Williams BG, Granich R.

Curr HIV Res. 2011 Sep;9(6):405-15. Review.

Items per page

Supplemental Content

Write to the Help Desk